Treatment of fibroids with hysteroscopic morcellation has pros and cons. For in-office treatment, the advantages and disadvantages are described here.
Though resection is still the most popular method of removing fibroids, the use of hysteroscopic morcellation has been on the rise since the first hysteroscopic morcellator became available in the United States in 2005.
Advantages of Morcellation
Morcellators use a blade and suction tube to simultaneously cut and remove tissue, which improves visibility and reduces the risk of perforations and gas embolus that are more likely with multiple equipment insertions.1 And because no energy is used in the uterine cavity, there is no risk of thermal injury.
Shorter operating time and ease of use are also among the principle advantages of the intra-uterine morcellator. 2,3 At an industry-sponsored breakfast at the 41st Global Congress of the American Association of Gynecologic Laparoscopists, AAGL’s past president Richard Gimpelson, MD, said, “If you can use an electric toothbrush, you can use [a] morcellator, that’s about how easy it is.”
Disadvantages of Morcellation
Morcellators cannot cauterize blood vessels and have limited utility in cases of Type II myomas.
For physicians wanting to use a hysteroscopic morcellator to perform in-office procedures, cost of the device and insurance reimbursement can be issues. Although the small size of the device makes it ideal for office procedures, the current system offers the same reimbursement rate for in-office and hospital or surgical-center procedures, which could make it cost-prohibitive for private practices.
Available Hysteroscopic Morcellation Systems
Currently, two morcellation systems are available in the United States: the TRUCLEAR™ Hysteroscopic Morcellator and the MyoSure® Tissue Removal System.
TRUCLEAR™ was the first to market in 2005, and the company released TRUCLEAR™ 5.0 in 2011. With an outer diameter 5 mm and a 2.9 mm morcellator, the TRUCLEAR™ 5.0 is presently the smallest morcellator on the market.
MyoSure® was first approved in 2009. Its system uses a 2mm morcellator and has an outer dimension of 6.25 mm.
1. Munro MG. Complications of hysteroscopic and uterine resectoscopic surgery. Obstet Gynecol Clin N Am.2010;37(3):399–425.
2. van Dongen H, Emanuel MH, Wolterbeek R, et al. Hysteroscopic morcellator for removal of intrauterine polyps and myomas: a randomized controlled pilot study among residents in training. J Minim Invasive Gynecol 2008; 15:466.
3. Emanuel MH, Wamsteker K. The Intra Uterine Morcellator: a new hysteroscopic operating technique to remove intrauterine polyps and myomas. J Minim Invasive Gynecol 2005; 12:62.
Phase 2b safety data for Sildenafil Cream against FSAD reported
August 26th 2024In a recent study published in The Journal of Sexual Medicine, Sildenafil Cream, 3.6% was indicated as safe and well-tolerated for use against female sexual arousal disorder in healthy premenopausal women.
Read More
Study: Pelvic floor dilator reduces pelvic floor muscle injury during vaginal delivery
August 6th 2024A new pilot study published in the International Urogynecology Journal found that Materna Medical’s Prep Device, a pelvic floor dilator, reduced full levator ani muscle avulsion during vaginal delivery in first-time mothers.
Read More
Similar success rates for synthetic and nonsynthetic slings in SUI treatment
July 31st 2024A study found that both synthetic and nonsynthetic slings show similar success rates for treating stress urinary incontinence in women, with synthetic slings demonstrating improved operative outcomes and reduced complications.
Read More
First hysterectomy using miniaturized MIRA Surgical System performed
July 30th 2024Virtual Incision Corporation has announced the successful performance of the first benign hysterectomy using their miniaturized robotic-assisted surgery device, MIRA, in a clinical trial assessing its safety and efficacy.
Read More